Why the study?
Does the CYP2C19*2 loss-of-function polymorphism reduce platelet responsiveness to clopidogrel in healthy white male volunteers?
Population
28 healthy young white male volunteers
Comparison
CYP2C19*2 loss-of-function polymorphism carrier… vs Wild-type CYP2C19 homozygote status, treated…
Design
Cohort
Follow-up
7 days
Authors
Loading...
CYP2C19*2 may contribute to clopidogrel resistance; leaves open whether genotyping should guide therapy in patients.
Does the CYP2C19*2 loss-of-function polymorphism reduce platelet responsiveness to clopidogrel in healthy white male volunteers?
The CYP2C19*2 loss-of-function allele significantly reduces platelet responsiveness to clopidogrel, identifying a major genetic basis for clopidogrel resistance.
Jean‐Sébastien Hulot (2006) studied this question.